Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
16.08
-1.02
(-5.95%)
At close: March 5 at 4:00:00 PM EST
Insider Roster
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
| Individual or Entity | Most Recent Transaction | Date | Shares Owned as of Transaction Date |
|---|---|---|---|
| HELTZEN MICHAEL Chief Executive Officer | Purchase | Jan 17, 2025 | 3,872 |
| MDB CAPITAL HOLDINGS, LLC Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Nov 8, 2024 | 3,931,130 |
| OPGENORTH PAUL HIDEO Officer | Conversion of Exercise of derivative security | Nov 8, 2024 | 640,504 |
Related Tickers
CUE Cue Biopharma, Inc.
1.1200
-4.27%
ASCLF Ascletis Pharma Inc.
0.8388
0.00%
PLRZ Polyrizon Ltd.
0.7704
+7.10%
CRTX.L CRISM Therapeutics Corporation
6.30
-3.08%
INTS Intensity Therapeutics, Inc.
2.3200
+4.98%
MAZE Maze Therapeutics, Inc.
11.87
+0.25%
IBO Impact BioMedical Inc.
1.1801
-18.05%
CTNM Contineum Therapeutics, Inc.
6.10
-2.40%
CHRO Channel Therapeutics Corporation
2.1600
-5.26%
UPB Upstream Bio, Inc.
8.47
+1.56%